On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
ThursdayOct 06, 2016 12:34 pm

Jaguar Animal Health, Inc. (JAGX) Signs LOI for Proposed Merger with Napo Pharmaceuticals, Inc.

Jaguar Animal Health (NASDAQ: JAGX) this morning announced its non-binding letter of intent with Napo Pharmaceuticals in a potential merger deal centered on Napo’s FDA-approved crofelemer for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Napo focuses on human product development and commercialization of proprietary pharmaceuticals, and has provided Jaguar with exclusive worldwide rights for veterinary applications to crofelemer – which is also the active pharmaceutical ingredient (API) in Jaguar’s lead prescription drug candidate, Canalevia™ for the treatment of various forms of diarrhea in dogs - as well as corresponding rights to all related Napo…

Continue Reading

ThursdayOct 06, 2016 12:32 pm

Inventergy Global, Inc. (INVT) Prices $6M Public Offering

As part of its plan of compliance with NASDAQ, Inventergy Global, Inc. (NASDAQ: INVT) this morning priced a registered public offering of $1 per common stock and warrant for gross proceeds of approximately $6.0 million. The IP company said it plans to use the net proceeds of the offering to redeem a portion of its outstanding Series C and Series E preferred stock and to fund operations. Company management also expects that approximately $5.3 million of the public offering will result in the company's stockholders' equity exceeding the NASDAQ requirement of $2.5 million. The warrants are exercisable immediately and for…

Continue Reading

WednesdayOct 05, 2016 12:51 pm

Amedica Corporation (AMDA) Cuts Workforce by 38%

Amedica Corporation (NASDAQ: AMDA), a technology company that manufactures and commercializes silicon nitride ceramic for biomedical applications, this morning announced that it has reduced its workforce by approximately 38% to lower its operating expenses. Amedica said it expects the reduction to save roughly $2 million on an annualized basis. Severance-related costs of approximately $465,000 will be recorded in Q4 2016. "We acknowledge the hard work of those affected by this decision, towards bringing silicon nitride technology to patient care," Dr. Sonny Bal, chairman and CEO of Amedica, stated in the news release. "Consistent with our previously-announced commitments, this prudent course,…

Continue Reading

WednesdayOct 05, 2016 12:50 pm

eXp World Holdings, Inc. (EXPI) Hosting Sold-Out Real Estate Conference

eXp World Holdings, Inc. (OTCQB: EXPI), owner of cloud-based real estate brokerage firm eXp Realty, recently announced changes to its leadership team as part of its strategy to continue its rapidly growing presence in the real estate market. Indicative of this growth, the company is currently hosting its third annual real estate conference in San Antonio, Texas, which sold out well before its opening. More than 600 of eXp Realty’s brokers and agents are expected to attend the conference, more than three times the number from last year’s event. This year’s conference is taking place October 5-7, 2016. To view…

Continue Reading

WednesdayOct 05, 2016 12:49 pm

Anavex Life Sciences Corp. (AVXL) Teams with Ariana Pharma to Advance Alzheimer’s and Parkinson’s Clinical Development Programs

Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, this morning announced its collaboration with Ariana Pharma (Cambridge, MA and Paris, France) in which Anavex will use Ariana’s proprietary, FDA-tested KEM® (Knowledge, Extraction, Management) patient stratification technology to potentially accelerate ANAVEX 2-73’s ongoing phase 2/3 Alzheimer’s clinical development timelines. KEM® is a comprehensive clinical data analysis system that enables full exploitation of complex datasets including of smaller numbers of patients. To view the full press release, visit: http://nnw.fm/4D42d About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (NASDAQ: AVXL)…

Continue Reading

WednesdayOct 05, 2016 12:48 pm

Immunomedics, Inc. (IMMU) Prices Underwritten Offering

Immunomedics (NASDAQ: IMMU) has priced an underwritten offering of 10 million shares of common stock and warrants to purchase up to 10 million shares of common stock at $3 per share for anticipated gross proceeds of $30 million. The company said it will use the proceeds from the offering to support clinical and regulatory activities for IMMU-132, including submission of a New Drug Application to the Food and Drug Administration for accelerated approval in metastatic triple-negative breast cancer, as well as for working capital and general corporate purposes. To view the full press release, visit: http://nnw.fm/vPH7a About Immunomedics, Inc. Immunomedics…

Continue Reading

WednesdayOct 05, 2016 12:46 pm

Innovus Pharmaceuticals, Inc. (INNV) Initiates Safety and Efficacy Study of Vesele® in Combination with Viagra®

Innovus Pharmaceuticals (OTCQB: INNV), a commercial-stage pharmaceutical company focused on over-the-counter medicines and consumer care products for men’s and women's health and respiratory diseases, has initiated a pre-clinical and clinical program to evaluate the safety and efficacy of its supplement Vesele® for promoting sexual health in combination with sildenafil indicated for treating erectile dysfunction. In the U.S., sildenafil is sold under the name Viagra® by Pfizer, Inc. (NYSE: PFE). In a previously announced human clinical survey to evaluate erectile dysfunction and sexual satisfaction in men using Vesele®, the drug showed favorable results. To view the full press release, visit: http://nnw.fm/nCgK6…

Continue Reading

TuesdayOct 04, 2016 12:37 pm

Net Element, Inc.’s (NETE) Aptito System Modernizes the Dining Scene

Net Element, Inc. (NASDAQ: NETE) is a technology-driven group with a glowing presence in the United States and select emerging countries. Within the company’s family of brands is Aptito, a cloud-based point of sale payments platform. Aptito’s next-generation functionalities are designed for restaurants and retail establishments looking to fully integrate digital capabilities into their operations. With the Aptito iPad point-of-sale (POS) system, customers can peruse a digital menu, order and pay from their Android mobile phone, iPad or iPod Touch. For the restaurant, this allows for streamlined operations, increased upselling opportunities, quicker turnaround, among many other features. For the full…

Continue Reading

TuesdayOct 04, 2016 12:36 pm

Netlist, Inc. (NLST) Pursues Importation Ban on SK Hynix, Inc. via ITC Investigation

Netlist, Inc. (NASDAQ: NLST) this morning announced that the U.S. International Trade Commission (ITC) is investigating the unfair trade practices of SK Hynix, Inc. related to its importation, sale for importation, and/or sale after importation of RDIMM and LRDIMM enterprise memory products.  The investigation seeks to determine whether these SK hynix products should be banned from importation into the United States by reason of infringement of six Netlist patents. ITC investigations proceed on an expedited basis, commonly progressing to trial within a year. To view the full press release, visit: http://nnw.fm/Uz2u8 About Netlist, Inc. Netlist creates solutions that accelerate turning…

Continue Reading

TuesdayOct 04, 2016 12:34 pm

Cellectar Biosciences, Inc. (CLRB) Granted Patent Allowance for CLR 1603

Cellectar Biosciences (NASDAQ: CLRB), an oncology-focused clinical stage biotech company, this morning announced that it has received from the U.S. Patent and Trademark Office (“USPTO”) a formal patent allowance for CLR 1603, which covers method of use for the treatment of a variety of solid tumors and associated cancer stem cells using the company’s phospholipid drug conjugate (“PDC”) delivery platform technology with paclitaxel.  The USPTO patent allowance covers method of use for breast, pancreatic, lung, colorectal and prostate cancers.  The company expects the full patent to be granted by the end of 2016. Cellectar earlier this year received patent allowance…

Continue Reading

Contact us: 212.418.1217